Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Net Assets
Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has net assets worth CN¥1.03 Billion CNY (≈ $151.00 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.91 Billion ≈ $279.37 Million USD) and total liabilities (CN¥877.24 Million ≈ $128.37 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.03 Billion |
| % of Total Assets | 54.05% |
| Annual Growth Rate | 21.0% |
| 5-Year Change | 109.87% |
| 10-Year Change | N/A |
| Growth Volatility | 25.02 |
Cheng Du Sheng Nuo Biotec Co. Ltd. A - Net Assets Trend (2017–2024)
This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Cheng Du Sheng Nuo Biotec Co. Ltd. A for the complete picture of this company's asset base.
Annual Net Assets for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)
The table below shows the annual net assets of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024. For live valuation and market cap data, see 688117 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥918.32 Million ≈ $134.38 Million |
+4.34% |
| 2023-12-31 | CN¥880.10 Million ≈ $128.79 Million |
+6.45% |
| 2022-12-31 | CN¥826.74 Million ≈ $120.98 Million |
+5.30% |
| 2021-12-31 | CN¥785.14 Million ≈ $114.89 Million |
+79.43% |
| 2020-12-31 | CN¥437.57 Million ≈ $64.03 Million |
+16.23% |
| 2019-12-31 | CN¥376.46 Million ≈ $55.09 Million |
+15.00% |
| 2018-12-31 | CN¥327.35 Million ≈ $47.90 Million |
+35.42% |
| 2017-12-31 | CN¥241.74 Million ≈ $35.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cheng Du Sheng Nuo Biotec Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 319.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥397.63 Million | 43.30% |
| Common Stock | CN¥112.42 Million | 12.24% |
| Other Components | CN¥408.29 Million | 44.46% |
| Total Equity | CN¥918.34 Million | 100.00% |
Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JOST Werke AG
XETRA:JST
|
$847.36 Million |
|
Xinjiang Yilite Industry Co Ltd
SHG:600197
|
$847.50 Million |
|
Bergman & Beving AB (publ)
ST:BERG-B
|
$847.70 Million |
|
Macmic Science & Technology Co Ltd
SHG:688711
|
$847.84 Million |
|
Pason Systems Inc.
TO:PSI
|
$847.01 Million |
|
Grupo Posadas S.A.B. de C.V
MX:POSADASA
|
$846.73 Million |
|
Azenta Inc
NASDAQ:AZTA
|
$846.61 Million |
|
Sanofi India Limited
NSE:SANOFI
|
$846.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cheng Du Sheng Nuo Biotec Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 879,928,271 to 918,343,435, a change of 38,415,164 (4.4%).
- Net income of 50,023,708 contributed positively to equity growth.
- Dividend payments of 34,166,640 reduced retained earnings.
- Other factors increased equity by 22,558,096.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥50.02 Million | +5.45% |
| Dividends Paid | CN¥34.17 Million | -3.72% |
| Other Changes | CN¥22.56 Million | +2.46% |
| Total Change | CN¥- | 4.37% |
Book Value vs Market Value Analysis
This analysis compares Cheng Du Sheng Nuo Biotec Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.45x to 4.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥2.95 | CN¥36.78 | x |
| 2018-12-31 | CN¥3.99 | CN¥36.78 | x |
| 2019-12-31 | CN¥3.36 | CN¥36.78 | x |
| 2020-12-31 | CN¥7.13 | CN¥36.78 | x |
| 2021-12-31 | CN¥9.89 | CN¥36.78 | x |
| 2022-12-31 | CN¥7.38 | CN¥36.78 | x |
| 2023-12-31 | CN¥7.76 | CN¥36.78 | x |
| 2024-12-31 | CN¥8.08 | CN¥36.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cheng Du Sheng Nuo Biotec Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.45%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.97%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.79x
- Recent ROE (5.45%) is below the historical average (9.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 14.02% | 17.43% | 0.56x | 1.44x | CN¥9.73 Million |
| 2018 | 9.12% | 10.74% | 0.58x | 1.46x | CN¥-2.87 Million |
| 2019 | 12.79% | 14.73% | 0.63x | 1.38x | CN¥10.49 Million |
| 2020 | 13.71% | 15.84% | 0.64x | 1.36x | CN¥16.24 Million |
| 2021 | 7.80% | 15.85% | 0.40x | 1.22x | CN¥-17.26 Million |
| 2022 | 7.80% | 16.30% | 0.36x | 1.34x | CN¥-18.19 Million |
| 2023 | 7.99% | 16.17% | 0.33x | 1.50x | CN¥-17.66 Million |
| 2024 | 5.45% | 10.97% | 0.28x | 1.79x | CN¥-41.81 Million |
Industry Comparison
This section compares Cheng Du Sheng Nuo Biotec Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,691,234,838
- Average return on equity (ROE) among peers: 6.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) | CN¥1.03 Billion | 14.02% | 0.85x | $847.06 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $903.62 Million | 4.28% | 2.45x | $1.16 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $441.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.87 Billion | 20.71% | 0.25x | $5.01 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.80 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $3.04 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $9.03 Billion | 25.71% | 0.43x | $13.75 Billion |
| Hainan Haiyao Co Ltd (000566) | $275.57 Million | 17.28% | 1.12x | $947.33 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $231.22 Million | -38.13% | 1.23x | $389.67 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.29 Billion | 2.31% | 2.07x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.32 Billion |
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more